Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, Blackstone EH, Harrington RA, Califf RM, Lauer MS. Peterson JG, et al. Among authors: roe mt. Am J Cardiol. 2001 Mar 1;87(5):532-6. doi: 10.1016/s0002-9149(00)01426-0. Am J Cardiol. 2001. PMID: 11230834 Clinical Trial.
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Roe MT, et al. Circulation. 2000 Sep 5;102(10):1101-6. doi: 10.1161/01.cir.102.10.1101. Circulation. 2000. PMID: 10973837
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Roe MT, et al. Eur Heart J. 2004 Feb;25(4):313-21. doi: 10.1016/j.ehj.2003.12.009. Eur Heart J. 2004. PMID: 14984920 Free article. Clinical Trial.
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
Ohman EM, Roe MT. Ohman EM, et al. Among authors: roe mt. Thromb Haemost. 2011 May;105(5):763-5. doi: 10.1160/TH11-03-0159. Epub 2011 Mar 10. Thromb Haemost. 2011. PMID: 21394382 No abstract available.
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M; PROTECTION AMI Investigators. Lincoff AM, et al. Eur Heart J. 2014 Oct 1;35(37):2516-23. doi: 10.1093/eurheartj/ehu177. Epub 2014 May 5. Eur Heart J. 2014. PMID: 24796339 Clinical Trial.
Management of non-Q-wave myocardial infarction.
Roe MT, Bowen TE, Topol EJ. Roe MT, et al. N Engl J Med. 1998 Nov 5;339(19):1396-7; author reply 1397-8. N Engl J Med. 1998. PMID: 9841308 No abstract available.
504 results